With over 76473.0 Profound Medical Corp. (PROF) shares trading Tuesday and a closing price of $12.84 on the day, the dollar volume was approximately $0.98 million. The shares have shown a positive half year performance of 59.90% and its price on 01/24/23 lost nearly -2.21%. Currently, there are 20.88M common shares owned by the public and among those 17.13M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for PROF have a consensus price objective of $11.49. The analysts have set the share’s price value over the next 12 months at a high of $15.00 and a low of $5.50. The average price target is 11.2% above its recent price level and a downside to the estimated low will see the stock lose -133.45% over that period. But an upside of 14.4% will see the stock hit the forecast high price target while median target price for the stock is $13.00.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Insiders at the company have transacted a total of 21 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 21 of these insider trades were purchases, accounting for 229,035 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Profound Medical Corp. are Fidelity True North Fund, First Asset JFT Strategies Fund, and Royce Micro Cap Fund. Fidelity True North Fund owns 1.13 million shares of the company’s stock, all valued at over $12.1 million. The company bought an additional 27200.0 shares recently to bring their total holdings to about 5.42% of the shares outstanding. First Asset JFT Strategies Fund bought 0.13 million shares to see its total holdings expand to 0.31 million shares valued at over $3.29 million and representing 1.48% of the shares outstanding. Royce Micro Cap Fund bought 9800.0 shares to bring its total holdings to over 0.21 million shares at a value of $2.27 million. Royce Micro Cap Fund now owns shares totaling to 1.02% of the shares outstanding.
Shares of Profound Medical Corp. (NASDAQ: PROF) opened at $12.50, down -$0.63 from a prior closing price of $13.13. However, the script later moved the day high at 13.03, down -2.21%. The company’s stock has a 5-day price change of 11.46% and 275.44% over the past three months. PROF shares are trading 17.91% year to date (YTD), with the 12-month market performance up to 32.10% higher. It has a 12-month low price of $3.10 and touched a high of $13.14 over the same period. PROF has an average intraday trading volume of 77.21K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.34%, 59.95%, and 83.43% respectively.
Institutional ownership of Profound Medical Corp. (NASDAQ: PROF) shares accounts for 52.76% of the company’s 20.88M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $268.05M. The earnings-per-share (ttm) stands at -$1.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.20% over the week and 8.38% over the month.
Analysts forecast that Profound Medical Corp. (PROF) will achieve an EPS of -$0.38 for the current quarter, -$0.39 for the next quarter and -$1.21 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.49 while analysts give the company a high EPS estimate of -$0.23. Comparatively, EPS for the current quarter was -$0.29 a year ago. Earnings per share for the fiscal year are expected to increase by 14.70%, and -3.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Profound Medical Corp. (PROF) as a “Strong Buy” at a consensus score of 1.70. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
